A long-term health study has found that seniors with a higher body mass index were less likely to make use of hospice care. Additionally, obese seniors spent significantly fewer days in hospice care than their nonobese counterparts.
A long-term health study has found that seniors with a higher body mass index (BMI) were less likely to make use of hospice care. Additionally, obese seniors spent significantly fewer days in hospice care than their nonobese counterparts.
This Health and Retirement Study (HRS) evaluated the association between BMI, hospice use, and Medicare expenditure among 5677 community-dwelling fee-for-service Medicare enrollees who died between 1998 and 2012. The primary outcomes evaluated by the researchers were:
According to senior author Jennifer Griggs, MD, MPH, hospice teams might require more staff to take care of people who are obese, “but Medicare hospice reimbursement is capped no matter what a person’s BMI.” Griggs also believes that obesity could potentially mask the typical signs and changes that physicians might use to determine the appropriate time to pass a patient on to hospice care. Although signs of cachexia might be visible even in an obese individual, the more gradual changes could be missed.
The authors reported the following for the decedent population in their study:
The lowest BMI group was used as the comparator for the 30 kg/m2 and ≥40 kg/m2 BMI groups.
“Obesity is a complex disease, and this study has shown another side of its effect on patients and the healthcare system. Patients with obesity are less likely to receive high-quality end-of-life care,” said John Harris, MD, MSc, who led the study during a fellowship at the University of Michigan. He is currently an assistant professor at the University of Pittsburgh School of Medicine.
Reference
Harris JA, Byhoff E, Perumalswami CR, Langa KM, Wright AA, Griggs JJ. The relationship of obesity to hospice use and expenditures: a cohort study [published online February 7, 2017]. Ann Intern Med. 2017. doi: 10.7326/M16-0749.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More